The name Kala comes from the Kalalau trail in Kauai, Hawaii, known for its strenuous path and difficult terrain but also for its beauty. The company is developing and commercializing therapeutics using their proprietary mucus-penetrating particle (MPP) technology with an initial focus on eye disease. MPPs are selectively sized with proprietary coatings, two characteristics the company believes enable even distribution of drug particles on mucosal surfaces and increase drug delivery to target tissues.
Kala created nanosuspensions of loteprednol etabonate (LE), a corticosteroid, with their MPP technology to generate two lead product candidates, INVELTYS (PI-121 1.0%) and KPI-121 0.25%. IVELTYS is for treating inflammation and pain after ocular surgery and KPI-121 0.25% is for temporary relief of dry eye disease signs and symptoms.
Iveltys which won FDA approval in 2018, is a new formulation of a topical steroid from Bausch Health which did not use nanoparticle technology. Iveltys is claimed to have better efficacy, safety and convenience for patients. Preliminary results from a Phase 3 study on KPI-121 are expected to be available in late 2019.
Documentaries, videos and podcasts